Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $11.00.

PSNL has been the subject of several analyst reports. Morgan Stanley reduced their target price on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Guggenheim lifted their price target on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Finally, Needham & Company LLC raised their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th.

Institutional Investors Weigh In On Personalis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Personalis during the fourth quarter worth about $31,000. Legal & General Group Plc purchased a new stake in shares of Personalis during the second quarter worth about $30,000. Ameritas Investment Partners Inc. bought a new stake in Personalis during the 2nd quarter valued at approximately $34,000. Finally, BNP Paribas Financial Markets raised its stake in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the period. 61.91% of the stock is owned by institutional investors.

Personalis Stock Performance

NASDAQ PSNL opened at $6.72 on Wednesday. The business’s fifty day moving average is $8.81 and its 200 day moving average is $8.24. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $11.50. The company has a market capitalization of $703.11 million, a PE ratio of -7.38 and a beta of 2.02.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%.The business had revenue of $17.35 million during the quarter, compared to analysts’ expectations of $17.12 million. On average, sell-side analysts forecast that Personalis will post -1.4 EPS for the current year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.